Cargando…

KRAS mutation status in colorectal cancer to predict response to EGFR targeted therapies: the need for a more precise definition

Detalles Bibliográficos
Autores principales:	Rouleau, E, Spyratos, F, Dieumegard, B, Guinebretière, J M, Lidereau, R, Bièche, I
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2607232/ https://www.ncbi.nlm.nih.gov/pubmed/19078954 http://dx.doi.org/10.1038/sj.bjc.6604815

Ejemplares similares

Traumatic Neurasthenia and Mental Disease: The Need for More Precise Definition
Publicado: (1915)

Concordance of KRAS/BRAF Mutation Status in Metastatic Colorectal Cancer before and after Anti-EGFR Therapy
por: Gattenlöhner, S., et al.
Publicado: (2009)

PIK3R1 underexpression is an independent prognostic marker in breast cancer
por: Cizkova, Magdalena, et al.
Publicado: (2013)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

EGFR Expression and KRAS and BRAF Mutational Status in Intestinal-Type Sinonasal Adenocarcinoma
por: Szablewski, Vanessa, et al.
Publicado: (2013)

Genomic and Transcriptional Alterations in Lung Adenocarcinoma in Relation to EGFR and KRAS Mutation Status
por: Planck, Maria, et al.
Publicado: (2013)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

The role of kras mutations and MSI status in diagnosis of colorectal cancer
por: Shemirani, Atena Irani, et al.
Publicado: (2011)

An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
por: Prencipe, Berardino, et al.
Publicado: (2023)

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
por: Chen, Yu, et al.
Publicado: (2015)

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
por: Kim, Mi-Jung, et al.
Publicado: (2012)

Clinical interest of KRAS mutation detection in blood for anti-EGFR therapies in metastatic colorectal cancer
por: Fiore, F Di, et al.
Publicado: (2008)

The prognostic values of EGFR expression and KRAS mutation in patients with synchronous or metachronous metastatic colorectal cancer
por: Huang, Ching-Wen, et al.
Publicado: (2013)

AMPK activation overcomes anti-EGFR antibody resistance induced by KRAS mutation in colorectal cancer
por: Ye, Hua, et al.
Publicado: (2020)

Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients
por: PAPADOPOULOU, EIRINI, et al.
Publicado: (2015)

Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS
por: Pinheiro, Gil, et al.
Publicado: (2020)

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma
por: Ribeiro, Karen Bento, et al.
Publicado: (2013)

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
por: Radanova, Maria, et al.
Publicado: (2023)

Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages
por: Li, Wenbin, et al.
Publicado: (2015)

Expression analysis of mitotic spindle checkpoint genes in breast carcinoma: role of NDC80/HEC1 in early breast tumorigenicity, and a two-gene signature for aneuploidy
por: Bièche, Ivan, et al.
Publicado: (2011)

Colorectal Cancer Patients with Low Abundance of KRAS Mutation May Benefit from EGFR Antibody Therapy
por: Yu, Shaorong, et al.
Publicado: (2013)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation
por: Huang, Chi-Jung, et al.
Publicado: (2016)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
por: Won, Daeyoun David, et al.
Publicado: (2017)

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
por: Mekenkamp, Leonie JM, et al.
Publicado: (2012)

PIK3CA Mutations Frequently Coexist with EGFR/KRAS Mutations in Non-Small Cell Lung Cancer and Suggest Poor Prognosis in EGFR/KRAS Wildtype Subgroup
por: Wang, Lei, et al.
Publicado: (2014)

CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons: Rapid way to detect EGFR and KRAS mutations
por: Ramteke, Manoj P., et al.
Publicado: (2016)

Prognostic value of CCND1 gene status in sporadic breast tumours, as determined by real-time quantitative PCR assays
por: Bièche, I, et al.
Publicado: (2002)

Correlation of EGFR or KRAS mutation status with (18)F-FDG uptake on PET-CT scan in lung adenocarcinoma
por: Takamochi, Kazuya, et al.
Publicado: (2017)

EGFR and KRAS mutations in pulmonary pleomorphic carcinoma and their correlation with clinicopathologic features
por: Jia, Xiaoli, et al.
Publicado: (2015)

EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2019)

Evaluation of EGFR, KRAS and BRAF gene mutations in renal cell carcinoma
por: Bayrak, Omer, et al.
Publicado: (2014)

Insights into EGFR Mutations and Oncogenic KRAS Mutations in Non-Small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations
por: Li, Wenbin, et al.
Publicado: (2015)

Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer?
por: Kim, Seung Tae, et al.
Publicado: (2015)

Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer
por: Lucchetti, Donatella, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bpdr3pegcasdqdbiu8266btf0r